Didanosine
规格
69655-05-6CAS 号
614-994-4EC 号
9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-oneIUPAC 名称
C10H12N4O3化学式
236.23 g/mol分子量
didanosine; 2',3'-Dideoxyinosine; 69655-05-6; DIDEOXYINOSINE; Videx; Inosine, 2',3'-dideoxy-; Videx EC; Didanosina; Didanosinum; ddIno; 2,3-dideoxyinosine; BMY-40900; (-)-didanosine; DTXSID6022927; NSC-612049; NSC 612049; K3GDH6OH08; BMY 40900; CHEBI:490877; NSC612049; BRN 3619529; 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one; DTXCID402927; 9-((2R,5S)-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one; 9-((2R,5S)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-1,9-dihydro-purin-6-one; 9-((2S,5R)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-9H-purin-6-ol; ddI (Antiviral); 9-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,9-dihydro-6H-purin-6-one; 9-[(2R,5S)-5-(HYDROXYMETHYL)OXOLAN-2-YL]-6,9-DIHYDRO-3H-PURIN-6-ONE; 2',3' Dideoxyinosine; Didanosine EC; 9-((2R,5S)-5-(hydroxymethyl)oxolan-2-yl)-6,9-dihydro-3H-purin-6-one; RefChem:55012; J05AF02; 614-994-4; DDI; 9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one; 2', 3'-dideoxyinosine; MFCD00077728; 9-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-6-ol; 9-[(2R,5S)-5-(HYDROXYMETHYL)OXOLAN-2-YL]-6,9-DIHYDRO-1H-PURIN-6-ONE; 9-[(2R,5R)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL]-1,9-DIHYDRO-6H-PURIN-6-ONE; NCGC00090691-03; NCGC00159514-02; 9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one; Hypoxanthine ddN; Didanosinum [INN-Latin]; Didanosina [INN-Spanish]; D2I; SMR000058576; Videx(TM); Intron A & Videx; CAS-69655-05-6; Videx (TN); PC-SOD+ddI; Dideoxyinosine (DDI); LOA & ddI; ddI & GM-CSF; SR-05000001487; DRG-0016; DDI and rIFN.alpha.2; ddI & sCD4(rsCD4); UNII-K3GDH6OH08; CCRIS 805; 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-purin-6-one; Didanosine RS; DS-4152 & ddI; Didanosine CRS; HSDB 6548; Didanosine [USAN:USP:INN:BAN]; Didanosine; 2',3'-dideoxyinosine; 9-(2,3-Dideoxy-beta-d-glycero-pentofuranosyl)-1,9-dihydro-6H-purin-6-one; 9-(2,3-Dideoxy-beta-D-ribofuranosyl)-6-oxopurine; Didanosine and Interferon-.alpha.-2; Videx EC(TM)(slow-release capsules); KS-1049; Didanosine (Standard); 2',3'-didesoxyinosin; 2',3'-Dideoxyinosine (AIDS Initiative); ddI & IFN-.alpha.; DIDANOSINE [MI]; DIDANOSINE [INN]; DIDANOSINE [JAN]; 2',3'-dideoxy-inosine; DIDANOSINE [HSDB]; DIDANOSINE [USAN]; DIDANOSINE [VANDF]; Epitope ID:768739; DIDANOSINE [MART.]; SCHEMBL3363; SCHEMBL3364; SCHEMBL3365; 2',3'-Dideoxy-D-inosine; CHEMBL1460; DIDANOSINE [USP-RS]; DIDANOSINE [WHO-DD]; DIDANOSINE [WHO-IP]; 9-(2,3-Dideoxy-beta-D-ribofuranosyl)hypoxanthine; Listera ovata agglutinin & 2',3'-Dideoxyinosine; Didanosine (JAN/USP/INN); MLS000759469; MLS001055350; MLS001424118; MLS002154216; MLS006011561; GTPL4833; orb1224212; orb1305302; SCHEMBL7866996; DIDANOSINE [EP IMPURITY]; DIDANOSINE [ORANGE BOOK]; SCHEMBL29387997; HY-B0249R; 2',3'-Dideoxyinosine & sCD4(soluble recombinant protein); DIDANOSINE [EP MONOGRAPH]; DIDANOSINE [USP IMPURITY]; DIDANOSINE [USP MONOGRAPH]; GLXC-08098; HMS2051J11; HMS2089N20; HMS2095O08; HMS2232P22; HMS3712O08; HMS3884M06; DIDANOSINUM [WHO-IP LATIN]; HY-B0249; Didanosine for system suitability RS; Tox21_111732; Tox21_202333; Tox21_300575; 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-3H-purin-6-one; BDBM50404252; EBC-13588; EBC-26267; EBC-44229; Didanosine for system suitability CRS; 2',3'-Dideoxyinosine & Granulocyte-macrophage colony-stimulating factor; 2',3'-DIDEOXYINOSINE; Didanosine; AKOS015833088; AKOS015901454; AKOS015963259; AKOS026750545; Tox21_111732_1; CCG-100947; CCG-220153; DB00900; NC00197; ND02929; 9-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3,9-dihydro-6H-purin-6-one; Didanosine 100 |Ig/mL in Acetonitrile; SRI-7013-04; SRI-7013-05; SRI-7013_07; NCGC00090691-01; NCGC00090691-02; NCGC00090691-14; NCGC00090691-15; NCGC00159514-03; NCGC00159514-04; NCGC00164280-01; NCGC00188983-01; NCGC00254496-01; NCGC00259882-01; NCGC00390773-01; 2DI; AC-12026; AC-32186; BP-58651; Didanosine 100 microg/mL in Acetonitrile; SMR004703324; 2',3'-Dideoxyinosine, >=98% (HPLC); 2',3'-Dideoxyinosine & Interferon-.alpha.; D3066; NS00000541; SW198619-2; C06953; D00296; EN300-123032; F326235; Q422606; SR-05000001487-1; SR-05000001487-2; BRD-K99063460-001-12-3; BRD-K99063460-001-13-1; Z1546616193; Didanosine, European Pharmacopoeia (EP) Reference Standard; Didanosine, United States Pharmacopeia (USP) Reference Standard; Inosine, 2',3'-dideoxy- & Recombinant Interferon-.alpha.-2; Lecithinized superoxide dismutase & Inosine, 2',3'-dideoxy-; 9-[(2R,5S)-5-(Hydroxymethyl)oxolan-2-yl]-1,9-dihydro-6H-purin-6-one; 9-((2R,5S)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL)-1H-PURIN-6(9H)-ONE; Didanosine for system suitability, European Pharmacopoeia (EP) Reference Standard; 2',3'-Dideoxy-1,9-dihydro-9-beta- D -ribofuranosyl-6 H -purin-6-one; 2',3'-Dideoxyinosine;同义词
